Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 35,516 shares of the biopharmaceutical company’s stock after selling 1,653 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Regeneron Pharmaceuticals were worth $27,414,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of REGN. Robeco Institutional Asset Management B.V. raised its holdings in Regeneron Pharmaceuticals by 153.4% during the third quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company’s stock worth $67,969,000 after purchasing an additional 73,176 shares in the last quarter. PGGM Investments grew its position in shares of Regeneron Pharmaceuticals by 9.7% during the third quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company’s stock worth $52,057,000 after acquiring an additional 8,187 shares during the last quarter. Sound Shore Management Inc CT purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $64,677,000. Rakuten Investment Management Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $33,121,000. Finally, Ellerson Group Inc. ADV grew its position in shares of Regeneron Pharmaceuticals by 49.2% during the third quarter. Ellerson Group Inc. ADV now owns 8,102 shares of the biopharmaceutical company’s stock worth $4,556,000 after acquiring an additional 2,671 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q1 beat on both profit and sales: non‑GAAP EPS $9.47 vs. consensus ~ $9.10 and revenue ~$3.6B (+19% y/y), driven by Dupixent strength. This is the primary catalyst supporting the stock today. Regeneron beats quarterly results estimates on strong Dupixent demand
• Positive Sentiment: Board approved up to $3.0B share repurchase program — a direct return‑of‑capital move that typically supports the share price. Analysts and headlines flagged the buyback alongside the earnings beat. Regeneron Pharmaceuticals Analysts Cut Their Forecasts Following Q1 Earnings
• Positive Sentiment: Quarterly cash dividend declared ($0.94 per share, record May 20, payable June 4) — adds a modest yield and supports income‑oriented holders.
• Neutral Sentiment: Pipeline updates: multiple C5 program milestones (PNH enrollment completion) and positive phase III data for cemdisiran in gMG with regulatory submissions underway — bullish for long‑term valuation but timing and commercial execution remain uncertain. Regeneron’s C5 Milestones And Autoimmune Bets Shape Future Valuation
• Neutral Sentiment: GAAP net income fell ~10% to $727M despite revenue growth (non‑GAAP metrics look stronger) — suggests some one‑time items/adjustments that investors should parse in the quarter’s detail. Regeneron Q1 2026 net income falls 10% to $727m
• Negative Sentiment: EYLEA concerns: U.S. sales of high‑dose EYLEA came in below expectations and total EYLEA sales declined y/y, highlighting intensifying competition in the retina market — this is why shares slipped immediately after the print for some investors. Regeneron Slumps On An Unexpected Setback For Its Bread-And-Butter Drug
• Negative Sentiment: Several firms trimmed price targets and forecasts post‑earnings (RBC, Wells Fargo, Truist, Barclays among others) — analysts cite mix shifts and competitive risk, which could cap near‑term upside despite the buyback. Analysts Cut Forecasts Following Q1 Earnings

Insider Activity at Regeneron Pharmaceuticals

In related news, SVP Jason Pitofsky sold 2,036 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the transaction, the senior vice president directly owned 4,272 shares in the company, valued at $3,325,837.44. This trade represents a 32.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.53, for a total transaction of $77,853.00. Following the completion of the transaction, the director owned 17,803 shares in the company, valued at approximately $13,860,169.59. This trade represents a 0.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,774 shares of company stock worth $2,942,738 in the last three months. Insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $707.06 on Friday. The firm’s fifty day moving average price is $756.81 and its 200 day moving average price is $735.17. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.15 and a quick ratio of 3.39. The firm has a market cap of $74.75 billion, a price-to-earnings ratio of 17.23, a price-to-earnings-growth ratio of 1.58 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same period last year, the firm posted $8.22 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 19.0% on a year-over-year basis. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.98 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Wednesday, May 20th will be given a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of research reports. Bank of America upgraded shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and raised their target price for the stock from $627.00 to $860.00 in a research report on Wednesday, January 7th. Guggenheim raised their target price on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Truist Financial lowered their target price on shares of Regeneron Pharmaceuticals from $801.00 to $796.00 and set a “buy” rating on the stock in a research report on Thursday. Evercore raised their target price on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research report on Thursday, January 22nd. Finally, Zacks Research lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $825.68.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.